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Background
In tumor cells, enhanced glutamine metabolism provides
anaplerotic carbon for the TCA and fatty acid synthesis
as well as precursors for the production of nucleotides
and glutathione. This metabolic alteration is primarily
driven by disruptions in oncogenic or tumor suppressor
function and ultimately results in glutamine dependency
for tumor cell growth and survival. Accordingly, identifi-
cation of small-molecule inhibitors targeting glutamino-
lysis3 may have utility as an anti-cancer therapeutic
strategy. Troglitazone, a PPARg agonist previously FDA-
approved in treating Type II diabetes, has been reported
to suppress glutamine metabolism. Therefore, we
examined whether troglitazone treatment could disrupt
glutamine metabolism and proliferation in glutamine-
dependent tumor cells.
Materials and methods
Using glutamine-dependent HeLa cervical cancer, H460
lung cancer, and RB-triple knock-out MEF cells, we
characterized the effects of troglitazone treatment on: 1)
cell viability, 2) glutamine metabolism by examining
14C-glutamine uptake, 13C-glutamine metabolomics, and
ATP determination, and 3) expression of ASCT2, GLS,
and c-Myc. To determine a PPAR requirement on these
processes, siRNA and pharmacological inhibition of
PPAR a or g was performed. Rescue experiments were
done through simultaneous add-back of di-methyl
alpha-ketoglutarate (a-KG) or expression of a c-Myc
phosphorylation mutant.
Results
Troglitazone treatment resulted in a dose-dependent
inhibition of cell proliferation and glutamine uptake that
was accompanied by a decrease in ASCT2 and GLS
expression. Metabolomics analysis revealed a reduction in
13C-glutamine incorporation into aspartate and a decrease
in steady-state ATP levels, suggesting that troglitazone
causes diminished glutamine anaplerosis within the TCA.
Silencing PPAR a or g activity via siRNA or a specific
small molecule antagonist (GW9662) did not alter trogli-
tazone’s effects on cell proliferation or glutamine uptake
suggesting that these processes are PPAR-independent.
However, troglitazone caused a dose-dependent, protea-
somal-mediated decrease in c-Myc expression, while
re-expression of a c-Myc phosphorylation mutant par-
tially rescued glutamine uptake, [ATP], and cell viability.
In addition, exogenous di-methyl a-KG also led to a par-
tial rescue of ATP and cell viability. Lastly, combinatorial
treatment with metformin, which sensitizes cells to gluta-
mine disruption, resulted in a synergistic decrease in cell
viability.
Conclusions
Taken together, troglitazone may exert its anti-tumor
activity in part through disruption of glutamine metabo-
lism in a PPAR-independent manner. In addition, charac-
terizing new anti-tumor properties of previously approved
FDA therapies lends support to the possible repurposing of
these agents, especially in combination with other targeted
treatment strategies, such as metformin.
Department of Biochemistry, JGBrown Cancer Center, University of Louisville,
Louisville, KY 40202, USA
Reynolds and Clem Cancer & Metabolism 2014, 2(Suppl 1):P61
http://www.cancerandmetabolism.com/content/2/S1/P61 Cancer & 
Metabolism
© 2014 Reynolds and Clem; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Published: 28 May 2014
doi:10.1186/2049-3002-2-S1-P61
Cite this article as: Reynolds and Clem: Troglitazone suppresses tumor
cell growth and glutamine metabolism through a PPAR-independent
mechanism. Cancer & Metabolism 2014 2(Suppl 1):P61.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Reynolds and Clem Cancer & Metabolism 2014, 2(Suppl 1):P61
http://www.cancerandmetabolism.com/content/2/S1/P61
Page 2 of 2
